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Severe and cerebral malaria is a global problem, claiming
at least 1 million lives annually. Case fatality rates are
high; around 10% in African children and 20% in adults
in SE Asia, but mortality is higher when multiple organs
are affected. Management of patients with severe malaria
can be divided into:
1. Antimalarial treatment; 2. Treatment of concomitant
diseases; 3. Supportive treatment; and 4. Adjunctive treat-
ments.
Prompt start of parenteral antimalarial is essential. The
antimalarial treatment of severe disease is being trans-
formed by the development and deployment of the water-
soluble artemisinin derivative artesunate. Parenteral
artesunate is now the treatment of choice in low-transmis-
sion areas and in the 2nd and 3rd trimesters of pregnancy,
and research is underway into whether it should replace
quinine as the treatment of choice in African children. The
development of artesunate suppositories may provide the
means to treat patients with severe disease in remote rural
settings, potentially buying the time needed to reach a
health care facility.
In areas of high transmission (sub-Saharan Africa), a sig-
nificant number of patients (up to 17%) with severe
febrile illness, including coma, in the presence of a
peripheral blood slide with asexual forms of P. falciparum
have concomitant bacteraemia. A high background preva-
lence of peripheral blood parasitaemia, as well as the pre-
disposition of severe malaria for bacteraemia contributes
to this. A low threshold for administration of broad spec-
trum antibiotics is warranted in this setting.
Adequate supportive care of complications, preferentially
in a high dependency or intensive care setting, is essential
to further safe lives. This includes prompt treatment of
hypoglycaemia and convulsions. Haemofiltration has
proven to be superior to peritoneal dialysis for treatment
of acute renal failure and invasive mechanical ventilation
is needed in case of ARDS, both feared complications of
adult severe malaria. Trials on optimal fluid management
and the timing of enteral feeding in cerebral malaria are
under way.
A large variety of adjunctive treatments based upon spe-
cific aspects severe malaria pathophysiology have been
tried, but none has proven to lower mortality, whereas
some were shown to be harmful. Many of the treatment
studies in severe malaria have been underpowered, which
should be avoided in the design of future trials. However,
only a limited number of interventions can be tested in
large multicenter multinational trials. This will necessitate
close collaboration between groups, as well as agreement
on the research agenda.
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